NPC1L1 and familial pancreatic carcinoma: Recently, a report by Rémy Nicolle and colleagues shows that compared to NPC1L1−/− tumor cells, ezetimibe could more effectively inhibit the proliferation of pancreatic tumor cells, indicating that the inhibition of NPC1L1 by ezetimibe may be an effective method for the treatment of pancreatic cancer (Nicolle et al., 2017).